Optimized Liposomal Dexamethasone Therapy Improves Functional Outcome of Post-Traumatic Skeletal Muscle and Neuromuscular Junction
Abstract
In this project(03/01/2017 to 08/31/2019), we performed our research experiments in four groups of mice including sham, tourniquet-induced IR+saline, tourniquet-induced IR+lipo-Dex, and tourniquet-induced IR+Dex groups. These experiments tested the protective effects oflipo-Dex and Dex on morphology and function of the skeletal muscle and neuromuscular junction in mice with tourniquet-induced IR. Lipo-Dex is liposome-encapsulated Dex. Our study found that lipo-Dex was mainly retained in IR-injured skeletal muscles after 24-hour ischemia/reperfusion (IR), lasted about 1 week, and then disappeared. Unilateral (left)hindlimb ischemia was induced in IR mice by placing an orthodontic rubber band (ORB) at thehip joint through use of a McGivney hemorrhoidal ligator. After 3 hours of ischemia, the ORB tourniquet was released to begin reperfusion for different periods. Treatment with Dex (1mg/kg/day, i.p. injection for 1 wk) or lipo-Dex (7mg/kg, one-time i.v., equivalent to 1 mg/kg/day of Dex for 1 wk) will begin at the beginning of reperfusion on the day of IR induction. Our data demonstrated that treatment of lipo-Dex or Dex suppresses IR-induced inflammation and promotes recovery of skeletal muscle and neuromuscular junction morphology and function from tourniquet-induced IR injury, especially no any side-effects for Lipo-Dex treatment. These experimental results suggest that the therapeutic addition of lipo-Dex supports the current policy of encouraging tourniquet use in combat and civilian medicine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2019
- Accession Number
- AD1106286
Entities
People
- Yulong Li
Organizations
- University of Nebraska Medical Center